No Picture
News

Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent Streptococcus pneumoniae Vaccine Candidate from Affinivax’s MAPS™ Platform

CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent Streptococcus pneumoniae Vaccine Candidate from Affinivax’s MAPS™ Platform Click here to view original post… […]

No Picture
News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., Feb. 28, 2022 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company approved the grant of stock options to purchase an aggregate of 168,500 shares of… Click here to view original post… […]

No Picture
News

KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)—- $KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented data for its lead oral drug candidate, KVD900, in development for on-demand treatment of hereditary angioedema (HAE), at the… Click here to view original post… […]

No Picture
News

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Feb. 28, 2022 /PRNewswire/ — Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels Durable serum TTR reductions observed with… Click here to view original post… […]

No Picture
News

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Cowen 42nd Annual Healthcare Conference on Tuesday, March 8, 2022 at 9:50 am ET, being held virtually Barclays Global Healthcare Conference on Tuesday, March 15, 2022… Click here to view original post… […]

No Picture
News

Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update

BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter and year ended December 31, 2021, and provided updates on its ophthalmology pipeline. “Ocular has… Click here to view original post… […]

No Picture
News

Quanterix Corporation Garners Five Best Places to Work Awards from Comparably

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has been recognized by leading workplace culture and corporate brand reputation platform, Comparably, in its 2021 Best Places to Work Awards. Based on more than 1,000… Click here to view original post… […]

No Picture
News

Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX™ LAAC Device

MARLBOROUGH, Mass., Feb. 28, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Presented during a late-breaking trial session… Click here to view original post… […]